Kalpit Patel
Stock Analyst at B. Riley Securities
(0.87)
# 3,897
Out of 5,012 analysts
59
Total ratings
32.56%
Success rate
-11.15%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kalpit Patel
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DERM Journey Medical | Maintains: Buy | $9 → $12 | $7.55 | +58.94% | 6 | Jul 30, 2025 | |
| KYMR Kymera Therapeutics | Upgrades: Buy | $38 → $60 | $56.92 | +5.41% | 5 | Jun 3, 2025 | |
| BCYC Bicycle Therapeutics | Maintains: Neutral | $17 → $14 | $8.00 | +75.00% | 7 | May 2, 2025 | |
| AVBP ArriVent BioPharma | Initiates: Buy | $37 | $19.31 | +91.61% | 1 | Mar 20, 2025 | |
| RIGL Rigel Pharmaceuticals | Maintains: Neutral | $20 → $24 | $29.50 | -18.64% | 6 | Mar 5, 2025 | |
| GERN Geron | Maintains: Buy | $5.5 → $3.5 | $1.29 | +171.32% | 4 | Feb 18, 2025 | |
| VSTM Verastem | Maintains: Buy | $7 → $9 | $9.00 | - | 4 | Jan 31, 2025 | |
| FHTX Foghorn Therapeutics | Initiates: Buy | $10 | $4.42 | +126.24% | 1 | Jan 30, 2025 | |
| PDSB PDS Biotechnology | Maintains: Buy | $9 → $7 | $0.96 | +625.99% | 5 | Nov 25, 2024 | |
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Buy | $85 → $40 | $14.61 | +173.79% | 2 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $3 | $1.67 | +79.64% | 2 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $20 | $21.00 | -4.76% | 3 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $90 → $30 | $3.44 | +772.09% | 1 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $34 → $36 | $16.45 | +118.84% | 2 | Jul 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $270 → $90 | $2.46 | +3,558.54% | 3 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $18 | $1.35 | +1,233.33% | 2 | Sep 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $5 | $1.89 | +164.55% | 2 | Jul 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $240 → $100 | $14.90 | +571.14% | 1 | Jan 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $75 | $14.23 | +427.06% | 2 | Sep 3, 2021 |
Journey Medical
Jul 30, 2025
Maintains: Buy
Price Target: $9 → $12
Current: $7.55
Upside: +58.94%
Kymera Therapeutics
Jun 3, 2025
Upgrades: Buy
Price Target: $38 → $60
Current: $56.92
Upside: +5.41%
Bicycle Therapeutics
May 2, 2025
Maintains: Neutral
Price Target: $17 → $14
Current: $8.00
Upside: +75.00%
ArriVent BioPharma
Mar 20, 2025
Initiates: Buy
Price Target: $37
Current: $19.31
Upside: +91.61%
Rigel Pharmaceuticals
Mar 5, 2025
Maintains: Neutral
Price Target: $20 → $24
Current: $29.50
Upside: -18.64%
Geron
Feb 18, 2025
Maintains: Buy
Price Target: $5.5 → $3.5
Current: $1.29
Upside: +171.32%
Verastem
Jan 31, 2025
Maintains: Buy
Price Target: $7 → $9
Current: $9.00
Upside: -
Foghorn Therapeutics
Jan 30, 2025
Initiates: Buy
Price Target: $10
Current: $4.42
Upside: +126.24%
PDS Biotechnology
Nov 25, 2024
Maintains: Buy
Price Target: $9 → $7
Current: $0.96
Upside: +625.99%
Corbus Pharmaceuticals Holdings
Sep 20, 2024
Maintains: Buy
Price Target: $85 → $40
Current: $14.61
Upside: +173.79%
Jun 18, 2024
Maintains: Buy
Price Target: $9 → $3
Current: $1.67
Upside: +79.64%
May 9, 2024
Downgrades: Neutral
Price Target: $25 → $20
Current: $21.00
Upside: -4.76%
Dec 12, 2023
Downgrades: Neutral
Price Target: $90 → $30
Current: $3.44
Upside: +772.09%
Jul 25, 2023
Maintains: Buy
Price Target: $34 → $36
Current: $16.45
Upside: +118.84%
Nov 11, 2022
Downgrades: Neutral
Price Target: $270 → $90
Current: $2.46
Upside: +3,558.54%
Sep 22, 2022
Maintains: Buy
Price Target: $21 → $18
Current: $1.35
Upside: +1,233.33%
Jul 19, 2022
Maintains: Buy
Price Target: $6 → $5
Current: $1.89
Upside: +164.55%
Jan 24, 2022
Maintains: Buy
Price Target: $240 → $100
Current: $14.90
Upside: +571.14%
Sep 3, 2021
Downgrades: Neutral
Price Target: $75
Current: $14.23
Upside: +427.06%